MGNX - MacroGenics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.84
+0.72 (+3.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close21.12
Open21.16
Bid21.92 x 1100
Ask22.40 x 800
Day's Range20.77 - 22.09
52 Week Range9.87 - 32.74
Volume1,385,723
Avg. Volume1,112,001
Market Cap1.163B
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.53
Earnings DateFeb 25, 2019 - Mar 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.09
Trade prices are not sourced from all markets
  • Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
    Zacksyesterday

    Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings

    CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.

  • Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
    Zacks3 days ago

    Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

    Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

  • MacroGenics' Public Offering to Raise Funds for R&D, Marketing Is a Smart Move
    GuruFocus.com3 days ago

    MacroGenics' Public Offering to Raise Funds for R&D, Marketing Is a Smart Move

    There are dozens of listed biotech and pharmaceutical companies with scant revenues that have managed to carry out public offerings to raise funding purely for research. MacroGenics Inc. (MGNX) is a classic example of one such company. With the recent spike in its stock price, and its upcoming offering, the stock is an excellent subject of analysis.

  • GlobeNewswire3 days ago

    MacroGenics to Participate in Guggenheim Healthcare Talks Idea Forum

    ROCKVILLE, MD, Feb. 13, 2019 --   MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...

  • GlobeNewswire4 days ago

    MacroGenics Announces Pricing of Public Offering of Common Stock

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions. In addition, MacroGenics has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. MacroGenics anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $110 million, excluding any exercise of the underwriters’ option to purchase additional shares.

  • GlobeNewswire4 days ago

    MacroGenics Announces Proposed Public Offering of Common Stock

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has commenced an underwritten public offering of shares of its common stock pursuant to its existing shelf registration statement. MacroGenics also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. The shares are being offered by MacroGenics pursuant to an effective shelf registration statement that was previously filed with the Securities and Exchange Commission (SEC).

  • Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
    Zacks5 days ago

    Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?

    Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.

  • Barrons.com8 days ago

    MacroGenics Soars in the Biotech Casino

    Positive trial results for a cancer drug boost shares by 130% in one day. Time for newer investors in the stock to take chips off the table?

  • MacroGenics Rose 130.42% on February 6
    Market Realist9 days ago

    MacroGenics Rose 130.42% on February 6

    MacroGenics Rose 130.42% on February 6Share price movements On February 6, MacroGenics (MGNX) closed at $25.60, which is 130.42% higher than the previous closing price, 159.37% higher than its 52-week low of $9.87, and 21.81% below its 52-week high

  • MacroGenics stock spikes from positive results of cancer drug trial
    American City Business Journals10 days ago

    MacroGenics stock spikes from positive results of cancer drug trial

    The successful late-stage trial is a big victory for the Rockville biotech, which focuses on antibody-based therapeutics to treat cancer.

  • TheStreet.com10 days ago

    MacroGenics Stock Soars on Positive Breast Cancer Trial Results

    Nomura sees the stock between $19 and $28 on positive Sophia results, Bloomberg says. Nomera and Leerink played lead roles in MacroGenics' public offering of 4,500,000 common shares priced at $21.25 in March 2018.

  • Biotech Stock Rockets 130% As It Takes On Roche In Breast Cancer
    Investor's Business Daily10 days ago

    Biotech Stock Rockets 130% As It Takes On Roche In Breast Cancer

    Macrogenics stock rocketed by triple digits Wednesday after the firm said its breast cancer treatment outperformed Roche's competing drug, the blockbuster Herceptin, in a late-stage study.

  • ETF Trends10 days ago

    Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results

    A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...

  • Barrons.com10 days ago

    What to Do When Your Biotech Stock Nearly Triples in a Day

    The latest big move in a volatile year for MacroGenics highlights the outsize risks and potential benefits of investing in clinical-stage biotech startups.

  • Why MacroGenics Stock Is Soaring Today
    Motley Fool10 days ago

    Why MacroGenics Stock Is Soaring Today

    A positive breast cancer trial readout sent this tiny biotech's shares rocketing higher.

  • ACCESSWIRE10 days ago

    4 Biotech Stocks Making Moves on Wednesday (2/6/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Pulmatrix Inc (PULM), MacroGenics Inc (MGNX), and Proteostasis Therapeutics Inc (PTI) represent four biotech companies creating nuanced approaches to further the advancement of modern medicine. The Company has seen impressive gains over the last few months as a result of momentum gained from several key strategic investments which demonstrate Premier's dedication to the betterment of the biotech industry, and more importantly, to consumers looking to enhance their quality of life. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced at the tail-end of last month that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • MarketWatch10 days ago

    MacroGenics stock up 110% after announcing positive Phase 3 trial results

    Shares of biotech MacroGenics Inc. shot up 110% in premarket trade Wednesday after the company announced that the Phase 3 trial of potential breast cancer treatment margetuximab met its primary endpoint. Margetuximab is the company's monoclonal antibody aimed at treating later-stage breast cancer patients who test positive for a protein called human epidermal growth factor receptor 2, or HER-2. A gene mutation that makes an excess of the HER-2 protein is present in about 15% of primary invasive breast cancers, according to UpToDate, an evidence-based medical resource used by clinicians. This particular trial showed longer progression-free survival in patients treated with a combination of margetuximab and chemotherapy compared to those on trastuzumab (brand name Herceptin) and chemotherapy, a standard-of-care treatment. The company also said approximately 85% of patients in the study were carriers of the CD16A 158F allele, a gene variation has been associated with a reduced clinical response to Herceptin and other antibodies. MacroGenics said it plans to submit a biologics license application to the U.S. Food and Drug Administration in the second half of 2019. Shares of MacroGenics have fallen 13% in the year to date, while the S&P 500 has gained 9.2%.

  • GlobeNewswire10 days ago

    MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of Margetuximab

    MacroGenics, Inc. (MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is an investigational immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc Optimization technology platform.

  • Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?
    Zacks12 days ago

    Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

    LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.

  • GlobeNewswire12 days ago

    Detailed Research: Economic Perspectives on Yum China, Tractor Supply, International Flavors & Fragrances, MacroGenics, Teekay Tankers, and WEX — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?
    Zacks16 days ago

    Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?

    We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.

  • Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
    Zacks18 days ago

    Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?

    On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.

  • Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
    Zacks19 days ago

    Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?

    Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.